Announcing a new publication for Acta Materia Medica journal. Chemoresistance to gemcitabine (Gem) remains a substantial obstacle in the treatment of pancreatic ductal adenocarcinoma carcinoma (PDAC).
Brusatol may serve as potential adjuvant therapy for pancreatic ductal adenocarcinoma
- Post author:
- Post published:September 29, 2024
- Post category:uncategorized